Bavarian Nordic A/S
CSE:BAVA
Bavarian Nordic A/S
Cash & Cash Equivalents
Bavarian Nordic A/S
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Cash & Cash Equivalents
kr1.6B
|
CAGR 3-Years
40%
|
CAGR 5-Years
40%
|
CAGR 10-Years
15%
|
|
|
Genmab A/S
CSE:GMAB
|
Cash & Cash Equivalents
kr9.9B
|
CAGR 3-Years
3%
|
CAGR 5-Years
23%
|
CAGR 10-Years
39%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Cash & Cash Equivalents
kr480.3m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-1%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Cash & Cash Equivalents
€559.5m
|
CAGR 3-Years
8%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
27%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Cash & Cash Equivalents
kr59.7m
|
CAGR 3-Years
9%
|
CAGR 5-Years
27%
|
CAGR 10-Years
9%
|
|
|
Saniona AB
STO:SANION
|
Cash & Cash Equivalents
kr303.3m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
50%
|
CAGR 10-Years
41%
|
|
Bavarian Nordic A/S
Glance View
Bavarian Nordic A/S, established in 1994, is a Danish biotechnology powerhouse distinguishing itself in the development and production of vaccines for infectious diseases and immunotherapies for cancer. The company's journey from a promising start-up to a respected player in the global biotech landscape has been driven by its commitment to innovation and strategic partnerships. Its core operations revolve around a sophisticated platform technology capable of developing vaccines quickly and efficiently. This cutting-edge technology enables Bavarian Nordic to address urgent public health needs, such as growing threats from infectious diseases like smallpox, monkeypox, and Ebola. The company's facility in Kvistgaard is crucial to its operations, allowing it to seamlessly transition from research and development to large-scale production, ensuring a quick response to global health challenges. Revenue generation for Bavarian Nordic is predominantly through contracts and collaborations with governments, health organizations, and pharmaceutical companies. Over the years, the company has secured significant agreements, such as those with the U.S. government for the supply of its smallpox and monkeypox vaccines. These contracts provide a steady income stream, allowing the company to reinvest in its R&D efforts and expand its vaccine pipeline. Moreover, Bavarian Nordic’s strategic acquisitions, like their purchase of Rabipur/RabAvert and Encepur from GlaxoSmithKline, have expanded their portfolio and market presence, providing additional revenue channels. This approach not only sustains the company's growth but also aligns with its long-term vision of addressing unmet medical needs worldwide. By continually leveraging its proprietary technology and expanding its network of strategic collaborations, Bavarian Nordic is well-positioned to advance its mission in the global healthcare arena.
See Also
What is Bavarian Nordic A/S's Cash & Cash Equivalents?
Cash & Cash Equivalents
1.6B
DKK
Based on the financial report for Dec 31, 2024, Bavarian Nordic A/S's Cash & Cash Equivalents amounts to 1.6B DKK.
What is Bavarian Nordic A/S's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
15%
Over the last year, the Cash & Cash Equivalents growth was 10%. The average annual Cash & Cash Equivalents growth rates for Bavarian Nordic A/S have been 40% over the past three years , 40% over the past five years , and 15% over the past ten years .
You don't have any saved screeners yet